Zynex Recognized in Top 100 Public Companies by ColoradoBiz PR Newswire LONE TREE, Colo., June 19, 2017 LONE TREE, Colo., June 19, 2017 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today that ColoradoBiz Magazine has recognized Zynex in Top100 Public Companies in its May/June 2017 issue. Zynex Zynex was ranked 90^th on 2016 revenue of $13.3 million up from 93^rd in 2015 on $11.6 million in revenue. Zynex previously announced estimated second quarter 2017 revenue of $3.8 million and EBITDA of $650,000. About ColoradoBiz For over 44 years, state officials, company executives and business professionals have looked to ColoradoBiz as the statewide voice of our business community. We are committed not only to highlighting the people, products, and companies that drive the economic future of our state, but helping Colorado businesses connect with each other and market themselves more effectively. About Zynex Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com. Safe Harbor Statement Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website. Contact: Zynex, Inc. (303) 703-4906 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zynex-recognized-in-top-100-public-companies-by-coloradobiz-300475637.html SOURCE Zynex Website: http://Zynex.com
Zynex Recognized in Top 100 Public Companies by ColoradoBiz
Press spacebar to pause and continue. Press esc to stop.